Results 51 to 60 of about 12,483,860 (378)

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

open access: yesExperimental and Therapeutic Medicine, 2017
As a key molecule involved in cell recognition, calreticulin (CRT) may be expressed on the surface of (pre-) apoptotic cells and provide the signal that is recognized by dendritic cells (DCs) or other antigen presenting cells (APCs), which results in ...
Jun Wang   +4 more
semanticscholar   +1 more source

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. [PDF]

open access: yes, 2007
Epstein-Barr virus (EBV) is associated with a number of human malignancies. EBV-positive post-transplant lymphoproliferative disease in solid organ and hematopoietic stem cell transplant recipients has been successfully treated by the adoptive transfer ...
Burdach, S.   +38 more
core   +1 more source

Unraveling the potential: mRNA therapeutics in oncology

open access: yesFrontiers in Oncology
Messenger ribonucleic acid (mRNA) technology is a promising platform for cancer immunotherapy. Unlike traditional vaccines that prevent infectious diseases, mRNA’s role in oncology is to stimulate or enhance the immune response against tumor antigens ...
Karol Gawalski   +7 more
doaj   +1 more source

Harnessing benefit from targeting tumor associated carbohydrate antigens

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Integrating additive or synergistic antitumor effects that focus on distinct elements of tumor biology are the most rational strategies for cancer treatment.
Thomas Kieber-Emmons   +4 more
doaj   +1 more source

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

open access: yesJournal of Translational Medicine, 2023
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells.
Gunjan Dagar   +16 more
doaj   +1 more source

A Tumor-Associated Antigen in Human Nephroblastomas [PDF]

open access: yesProceedings of the National Academy of Sciences, 1973
Antisera prepared against extracts of human nephroblastomas (Wilms' tumors) allowed the characterization in these extracts, and in a few extracts of tumors of other organs, of a tumor-associated antigen. This antigen is different from all previously described antigens, and was named W antigen (W for Wilms).
P, Burtin, M C, Gendron
openaire   +2 more sources

Tumor microenvironment antigens

open access: yes, 2023
The identification and characterization of tumor antigens are central objectives in developing anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered relatively restricted to tumor cells (i.e., overexpressed proteins in
Mads Hald Andersen, Andersen, Mads Hald
core   +1 more source

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C

open access: yesJournal of Pharmaceutical Analysis, 2023
Glioblastoma (GBM) is a lethal cancer with limited therapeutic options. Dendritic cell (DC)-based cancer vaccines provide a promising approach for GBM treatment.
Ping Zhu   +22 more
doaj   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

Immunoblotting in Detection of Tumor-Associated Antigens in Esophageal Squamous Cell Carcinoma

open access: yes, 2020
Tumor-associated antigens (TAAs) can be used as cancer markers and as signposts of therapeutic targets since their inimitable expression in cancer or significant overexpression in esophageal squamous cell carcinoma (ESCC) correlates with the initiation ...
Islam, F   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy